Exhibit 99.1 

NOTICE OF

SPECIAL GENERAL MEETING OF SHAREHOLDERS

AND HOLDERS OF SERIES 10 WARRANTS

TO BE HELD ON NOVEMBER 26, 2015

To the shareholders, ADS holders and Series 10 Warrant holders of Can-Fite BioPharma Ltd.:

Notice is hereby given that a Special Meeting of Shareholders will be held on Thursday, November 26, 2015, at 4.00 p.m. Israel time at our offices, 10 Bareket Street, Petach Tikva, Israel and a Special Meeting of Series 10 Warrant Holders will be held on Thursday, November 26, 2015, at 4.30 p.m. Israel time at our offices, 10 Bareket Street, Petach Tikva.

The agenda of the special general meeting will be as follows:

Only shareholders, holders of American Depositary Shares, and Series 10 Warrant holders at the close of business on October 29, 2015 are entitled to notice of, and to vote at, the special meeting and any adjournment or postponement thereof. You are cordially invited to attend the special meeting in person.

If you are unable to attend the special meeting in person, you are requested to complete, date and sign the enclosed proxy and to return it promptly in the pre-addressed envelope provided. Shareholders or Series 10 Warrant holders who attend the special meeting may revoke their proxies and vote their shares in person.

Beneficial owners who hold ordinary shares or Series 10 Warrants through members of the Tel Aviv Stock Exchange, or the TASE, may either vote their shares or Series 10 Warrants in person at the special meeting by presenting a certificate signed by the TASE Clearing House member through which the shares or Series 10 Warrants are held, which complies with the Israel Companies Regulations (Proof of Ownership for Voting in General Meetings)-2000 as proof of ownership of the shares on the record date, or send such certificate along with a duly executed proxy (in the form filed by us on MAGNA, the distribution site of the Israeli Securities Authority, at www.magna.isa.gov.il), to us at 10 Bareket Street, Kiryat Matalon, PO Box 7537, Petach Tikva,4951778, Israel Attention: Chief Financial Officer.

10 Bareket Street, Kiryat Matalon

PO Box 7537

Petach Tikva 4951778

Israel

PROXY STATEMENT

FOR SPECIAL GENERAL MEETING OF SHAREHOLDERS

AND HOLDERS OF SERIES 10 WARRANTS

TO BE HELD ON NOVEMBER 26, 2015

This Proxy Statement is furnished to our holders of ordinary shares, par value NIS 0.25 per share, including holders of our ordinary shares that are represented by American Depository Shares, or ADSs, and holders of Series 10 Warrants in connection with the Special General Meeting of Shareholders and Holders of Series 10 Warrants, to be held on Thursday, November 26, 2015 at our offices, 10 Bareket Street, Petach Tikva, Israel, or at any adjournments thereof. The Special General Meeting of Shareholders shall be held at 4.00 p.m. on such day or at any adjournments thereof and the Special General Meeting of Series 10 Warrant holders shall be held at 4.30 p.m. on such day or at any adjournments thereof.

Throughout this Proxy Statement, we use terms such as “Can-Fite”, “we”, “us”, “our” and the “Company” to refer to Can-Fite Bio Pharma Ltd. and terms such as “you” and “your” to refer to our shareholders, ADS holders and our holders of Series 10 Warrants.

Agenda Items

The agenda of the special meeting will be as follows:

We currently are unaware of any other matters that may be raised at the special meeting. Should any other matters be properly raised at the special meeting, the persons designated as proxies shall vote according to their own judgment on those matters.

Board Recommendation

Our board of directors unanimously recommends that you vote “FOR” each of Proposals 1 and 2.

Who Can Vote

Only shareholders, ADS holders and Series 10 Warrant holders at the close of business on October 29, 2015, shall be entitled to receive notice of and to vote at the special meeting.

How You Can Vote

You can vote your ordinary shares and Series 10 Warrants by attending the special meeting. If you do not plan to attend the special meeting, the method of voting will differ for shares or Series 10 Warrants held as a record holder, shares or Series 10 Warrants held in “street name” (through a Tel Aviv Stock Exchange, or TASE, member) and shares underlying ADSs that you hold. Record holders of shares and Series 10 Warrants will receive proxy cards. Holders of shares or Series 10 Warrants in “street name” through a TASE member will also vote via a proxy card, but through a different procedure (as described below). Holders of ADSs (whether registered in their name or in “street name”) will receive voting instruction cards in order to instruct their banks, brokers or other nominees on how to vote.

Shareholders/Series 10 Warrant Holders of Record

If you are a shareholder or Series 10 Warrant holder of record, you can submit your vote by completing, signing and submitting an applicable proxy card, which has been published at www.magna.isa.gov.il and www.maya.tase.co.il and which will be accessible at the “Investor Information” portion of our website, as described below under “Shareholder Meetings”.

Please follow the instructions on the applicable proxy card.

Shareholders/Series 10 Holders Holding in “Street Name,” Through the TASE

If you hold ordinary shares or Series 10 Warrants in “street name,” that is, through a bank, broker or other nominee that is admitted as a member of the TASE, your shares or Series 10 Warrants will only be voted if you provide instructions to the bank, broker or other nominee as to how to vote, or if you attend the special meeting in person.

If voting by mail, you must sign and date an applicable proxy card in the form filed by us on MAGNA on or around October 26, 2015 and attach to it a certificate signed by the TASE Clearing House member through which the shares or Series 10 Warrants are held, which complies with the Israel Companies Regulations (Proof of Ownership for Voting in General Meetings)-2000 as proof of ownership of the shares or Series 10 Warrants, as applicable, on the record date, and return the applicable proxy card, along with the proof of ownership certificate, to us, as described in the instructions available on MAGNA.

If you choose to attend the special meeting (where ballots will be provided), you must bring the proof of ownership certificate from the TASE’s Clearing House member through which the shares or Series 10 Warrants are held, indicating that you were the beneficial owner of the shares or Series 10 Warrants, as applicable, on the record date.

Holders of ADSs

Under the terms of the Deposit Agreement between the Company, The Bank of New York Mellon, as depositary, or BNY Mellon, and the holders of our ADSs, BNY Mellon shall endeavor (insofar as is practicable) to vote or cause to be voted the number of shares represented by ADSs in accordance with the instructions provided by the holders of ADSs to BNY Mellon. For ADSs that are held in “street name”, through a bank, broker or other nominee, the voting process will be based on the underlying beneficial holder of the ADSs directing the bank, broker or other nominee to arrange for BNY Mellon to vote the ordinary shares represented by the ADSs in accordance with the beneficial holder’s voting instructions. If no instructions are received by BNY Mellon from any holder of ADSs (whether held directly by a beneficial holder or in “street name”) with respect to any of the shares represented by the ADSs on or before the date established by BNY Mellon for such purpose, BNY Mellon shall not vote or attempt to vote the shares represented by such ADSs.

Multiple Record Holders or Accounts

You may receive more than one set of voting materials, including multiple copies of this document and multiple proxy cards or voting instruction cards. For example, shareholders who hold ADSs in more than one brokerage account will receive a separate voting instruction card for each brokerage account in which ADSs are held. Shareholders or Series 10 Warrant holders of record whose shares or Series 10 Warrants are registered in more than one name will receive more than one proxy card. You should complete, sign, date and return each proxy card and voting instruction card you receive.

Our board of directors urges you to vote your shares or Series 10 Warrants so that they will be counted at the special meeting or at any postponements or adjournments of the special meeting.

Solicitation of Proxies

By appointing “proxies”, shareholders, ADS holders and Series 10 Warrant holders may vote at the special meeting whether or not they attend. If a properly executed proxy in the attached form is received by us at least 48 hours prior to the special meeting (and received by BNY Mellon no later than the date indicated on the voting instruction card, in the case of ADS holders), all of the shares or Series 10 Warrants represented by the proxy shall be voted as indicated on the form or, if no preference is noted, shall be voted in favor of the matter described above, and in such manner as the holder of the proxy may determine with respect to any other business as may come before the special meeting or any adjournment thereof. Shareholders, ADS holders and Series 10 Warrant holders may revoke their proxies at any time before the deadline for receipt of proxies by filing with us (in the case of holders of ordinary shares or Series 10 Warrants) or with BNY Mellon (in the case of holders of ADSs), a written notice of revocation or duly executed proxy bearing a later date.

Proxies are being distributed to shareholders, ADS holders and Series 10 Warrant holders on or about October 27, 2015. Certain officers, directors, employees, and agents of ours, none of whom will receive additional compensation therefor, may solicit proxies by telephone, emails, or other personal contact. We will bear the cost for the solicitation of the proxies, including postage, printing, and handling, and will reimburse the reasonable expenses of brokerage firms and others for forwarding material to beneficial owners of shares, ADSs and Series 10 Warrants.

To the extent you would like to submit a position statement with respect to the proposal described in this proxy statement pursuant to the Israeli Companies law, 1999, or the Israeli Companies Law, you may do so by delivery of appropriate notice to the our offices (Attention: Chief Financial Officer) located at 10 Bareket Street, Kiryat Matalon, PO Box 7537, Petach Tikva 4951778, Israel, not later than ten days after the record date (i.e., November 8, 2015). Response of the Board to the position statement may submitted not later than five days after the deadline for sending the position statement (i.e., November 12, 2015).

Quorum

At the close of business on October 25, 2015, we had outstanding 27,672,901 ordinary shares, of which 18,804,120 were represented by ADSs. The foregoing number of outstanding ordinary shares excludes 446,827 ordinary shares that are held in treasury and have no voting rights. Each ordinary share (including ordinary shares represented by ADSs) outstanding as of the close of business on the record date are entitled to one vote upon each of the matters to be voted on at the special meeting.

Under our articles of association, the special meeting with respect to the shareholders meeting will be properly convened if at least two shareholders attend the meeting in person or sign and return proxies, provided that they hold shares representing at least 25% of our shareholder voting power. The special meeting with respect to the Series 10 Warrant holders meeting will be properly convened if at least two Series 10 Warrant holders attend the meeting in person or sign and return proxies, provided that they hold Series 10 Warrants representing at least 25% of our Series 10 Warrant voting power. If such quorum is not present within half an hour from the time scheduled for the meeting, the meeting will be adjourned for one week (to the same day, time and place), or to later date if so specified in the notice of the meeting. At the reconvened meeting, if there is no quorum within half an hour from the time scheduled for the meeting, any number of our shareholders or Series 10 Warrant holders, as applicable, present in person or by proxy shall constitute a lawful quorum.

Vote Required for the Proposal

The affirmative vote of our shareholders and ADS holders of a majority of the voting power represented at the special meeting in person or by proxy and voting thereon (which excludes abstentions) is necessary for the approval of Proposal 1.

The affirmative vote of our shareholders, ADS holders and Series 10 Warrant holders of at least 75% of the voting power represented at the special meeting in person or by proxy and voting thereon (which excludes abstentions) is necessary for the approval of Proposal 2. Shareholders, ADS holders and Series 10 Warrant holders will be required to declare concurrent holdings of both shares or ADSs on the one hand and Series 10 Warrants on the other. If necessary, results will be calculated on the basis of unmingling of the share and Series 10 Warrant votes.

If you provide specific instructions (mark boxes) with regard to certain proposals, your shares will be voted as you instruct.

If you are a shareholder or Series 10 Warrant holder of record and do not return your proxy card, your shares will not be voted. If you hold shares (or ADSs representing shares) or Series 10 Warrants beneficially in street name, your shares will also not be voted at the meeting if you do not return your proxy card or voting instruction card to instruct your broker or the Depositary how to vote. A broker (and BNY Mellon) may only vote in accordance with instructions from a beneficial owner of shares, ADSs or Series 10 Warrants.

Availability of Proxy Materials

Copies of the applicable proxy card and voting instruction card, the Notice of the Special General Meeting and this Proxy Statement are available at the “Investor Information” portion of our website, www.canfite.com. The contents of that website are not a part of this Proxy Statement.

Reporting Requirements

We are subject to the information reporting requirements of the Securities Exchange Act of 1934, as amended, or Exchange Act, applicable to foreign private issuers. We fulfill these requirements by filing reports with the Securities and Exchange Commission, or Commission. Our filings with the Commission may be inspected without charge at the Commission’s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. Information on the operation of the Public Reference Room can be obtained by calling the Commission at 1-800-SEC-0330. Our filings are also available to the public on the Commission’s website at http://www.sec.gov.

As a foreign private issuer, we are exempt from the rules under the Exchange Act related to the furnishing and content of proxy statements. The circulation of this notice and proxy statement should not be taken as an admission that we are subject to the proxy rules under the Exchange Act.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table sets forth information regarding the beneficial ownership of our outstanding ordinary shares as of October 25, 2015 by the members of our senior management, and board of directors, individually and as a group, and each person who we know beneficially owns 5% or more of our outstanding ordinary shares. The beneficial ownership of ordinary shares is based on the 27,672,901 ordinary shares outstanding as of October 25, 2015 (which excludes 446,827 ordinary shares held in treasury) and is determined in accordance with the rules of the Commission and generally includes any ordinary shares over which a person exercises sole or shared voting or investment power. For purposes of the table below, we deem shares subject to options or warrants that are currently exercisable or exercisable within 60 days of October 25, 2015, to be outstanding and to be beneficially owned by the person holding the options or warrants for the purposes of computing the percentage ownership of that person but we do not treat them as outstanding for the purpose of computing the percentage ownership of any other person.

PROPOSAL TO INCREASE AUTHORIZED SHARE CAPITAL

Background

Our authorized share capital is NIS 10,000,000 divided into 40,000,000 ordinary shares, par value NIS 0.25 each. As of October 25, 2015, 27,672,901 ordinary shares were outstanding (excluding 446,827 ordinary shares that are held in treasury) and after taking into account ordinary shares issuable upon exercise of outstanding options and warrants, we have 502,857 ordinary shares available for future issuance. Accordingly, our board of directors recommends that our shareholders increase our authorized share capital by NIS 10,000,000 such that following the increase, our authorized share capital shall equal NIS 20,000,000 divided into 80,000,000 ordinary shares.

The increase in authorized share capital would allow us to meet our future business needs as they arise. These purposes could include, among other things, the sale of shares in public and private offerings to raise additional capital, the purchase of property or assets, the acquisition of other companies, the use of shares for various equity compensation and other employee benefit plans and arrangements, the declaration of share splits or dividends, and other bona fide corporate purposes.

Proposed Resolution

It is proposed that at the special meeting the following resolution be adopted:

“RESOLVED, that the increase to our authorized share capital by NIS 10,000,000, such that following the increase, the authorized share capital shall equal NIS 20,000,000 divided into 80,000,000 ordinary shares, par value NIS 0.25 each., and the corresponding amendment to our articles of association be, and hereby is, approved in all respects.”

Board Recommendation

Our board of directors recommends a vote FOR the foregoing proposal.

PROPOSAL TO AMEND THE TERMS OF THE SERIES 10 WARRANTS

Background

As of October 25, 2015, there are outstanding 39,042,000 Series 10 Warrants to purchase 1,561,680 ordinary shares, NIS 0.25 per share, outstanding, exercisable at NIS 0.394 (which may fluctuate as it is based on the Israeli consumer price index) per ordinary share. Under the terms of these warrants, the expiration date was originally October 31, 2015 and these warrants can be exercised on any trading day except the 12^th and 16^th of each calendar month.

On October 8, 2015, we filed an application with the Lod District Court in Israel, or the Court, to approve the convening of a special general meeting of our shareholders and a general meeting of our Series 10 Warrant holders to approve an extension of the term of our Series 10 Warrants until October 31, 2016 which was set to expire on October 31, 2015. The application was made in accordance with the provisions of Section 350 of the Israeli Companies Law – 1999. As part of the application, we also requested the Court to extend the term of our Series 10 Warrants until December 31, 2015 as temporary relief. On the same day, the Court approved our application to extend the term of the Series 10 Warrants until December 31, 2015. Subsequently, on October 13, 2015, the Court approved our application to convene the foregoing meeting. On the same day, we requested that the Court additionally allow us to include in the convening of such meeting a proposal to eliminate the restrictions upon the days in which the warrants can be exercised such that the warrants can be exercised on any trading day. On October 18, 2015, the Court approved this request.

The amendment to the terms of the Series 10 Warrants is being made primarily to allow more time for the holders to exercise their warrants with a view to providing us with additional funds if and when such warrants are exercised.

Proposed Resolution

It is proposed that at the special meeting the following resolution be adopted:

“RESOLVED, that the amendment to the terms of the Series 10 Warrants by extending the expiration date of the Series 10 Warrants from October 31, 2015 to October 31, 2016 and allowing the Series 10 Warrants to be exercised on any trading day, be, and hereby is, approved in all respects.”.

Board Recommendation

Our board of directors recommends a vote FOR the foregoing proposal.

OTHER BUSINESS

Other than as set forth above, as of the mailing of this Proxy Statement, management knows of no business to be transacted at the special meeting, but, if any other matters are properly presented at the special meeting, the persons named in the enclosed form of proxy will vote upon such matters in accordance with their best judgment.